The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary–adrenal activity in humans with psychotic major depression
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction Hypothalamic-pituitary-adrenal (HPA) axis dysregulation has been linked with major depression, particularly psychotic major depression (PMD), with mineralocorticoid receptors (MRs) playing a role in HPA-axis regulation and the pathophysiology of depression. Herein we hypothesize that the MR agonist fludrocortisone differentially inhibits the HPA axis of psychotic major depression subjects (PMDs), non-psychotic major depression subjects (NPMDs), and healthy control subjects (HCs). Methods Fourteen PMDs, 16 NPMDs, and 19 HCs were admitted to the Stanford University Hospital General Clinical Research Center. Serum cortisol levels were sampled at baseline and every hour from 18:00 to 23:00 h, when greatest MR activity is expected, on two consecutive nights. On the second afternoon at 16:00 h all subjects were given 0.5 mg fludrocortisone. Mean cortisol levels pre- and post-fludrocortisone and percent change in cortisol levels were computed. Results There were no significant group differences for cortisol at baseline: F (2,47) = .19, p= .83. There were significant group differences for post-fludrocortisone cortisol: F (2,47) = 5.13, p = .01, which were significantly higher in PMDs compared to HCs (p = .007), but not compared to NPMDs (p = .18). There were no differences between NPMD’s and HC’s (p= .61). Also, PMDs had a lower percent change from baseline in cortisol levels at 2200 hrs than NPMDs (p =.01) or HCs (p = .009). Conclusions Individuals with psychotic major depression compared to healthy control subjects have diminished feedback inhibition of the hypothalamic-pituitary-adrenal (HPA) axis in response to the mineralocorticoid receptor agonist fludrocortisone. To our knowledge, this is the first study to examine HPA axis response to MR stimulation in major depression (with and without psychosis), and only the third study to demonstrate that exogenously administered fludrocortisone can down-regulate the HPA axis in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Heim, C. (2000) · JAMA · doi:10.1001/jama.284.5.592 · Cited by 1,968 · cited 2×
“The lack of cortisol differences at baseline in contrast to differences in response to fludrocortisone is also consistent with other studies of HPA activity in depression, in which subjects demonstrate more dramatic differences in response to a psychological or pharmacological challenge (Carroll, 1982; Heim et al., 20…”
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654 · cited 1×
“…with major depression have higher cortisol secretion in response to the MR antagonist spironolactone compared to healthy individuals; and Holsboer (1999) reported that spironolactone decreases the antidepressant efficacy of amitriptyline, a potent antidepressant in persons with major…”
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356 · cited 2×
“Nelson and Davis found that 64% of study participants with psychotic major depression did not suppress cortisol in response to exogenous dexamethasone, compared to 41% of participants with non-psychotic major depression (NPMD) (Nelson and Davis, 1997).”
An open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Self-citationBinneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254
Mineralocorticoid Receptor Function in Major Depression
Young, E. A., Lopez, J. F., Murphy-Weinberg, V., Watson, S. J., & Akil, H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.24 · Cited by 204 · cited 1×
“Young et al. (2003) showed that individuals with major depression have higher cortisol secretion in response to the MR antagonist spironolactone compared to healthy individuals; and Holsboer (1999) reported that spironolactone decreases the antidepressant efficacy of amitriptyline, a potent…”
Metyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial
Jahn, H., Schick, M., Kiefer, F., Kellner, M., Yassouridis, A., & Wiedemann, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.12.1235 · Cited by 184
DeBattista, C., Belanoff, J., Glass, S., Khan, A., Horne, R. L., Blasey, C., Carpenter, L. L., & Alva, G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.034 · Cited by 162
Cited by
Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., & Schatzberg, A. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.120 · Cited by 922
“Furthermore, PMD patients demonstrate a blunted response to fludrocortisone, a mixed mineralocorticoid/ glucocorticoid agonist (12, 14), high rates of non-suppression on challenge with dexamethasone, with particularly high post-dexamethasone cortisol levels (13).”
BackgroundSelf-citationThe brain mineralocorticoid receptor and stress resilience
ter Heegde, F., De Rijk, R. H., & Vinkers, C. H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.10.022 · Cited by 187
HPA axis genetic variation, cortisol and psychosis in major depression
Schatzberg, A. F., Keller, J., Tennakoon, L., Lembke, A., Williams, G., Kraemer, F. B., Sarginson, J. E., Lazzeroni, L. C., & Murphy, G. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.129 · Cited by 131
“PMD patients have been reported to demonstrate significantly elevated 24-hour urinary free cortisol levels (1), plasma adrenocorticotropin hormone (ACTH) levels (11), afternoon (1-4 pm) cortisol levels (4), nocturnal serum cortisol levels (6), blunted response to a mineralocorticoid agonist (7), as well as high rates…”
Self-citationOtte, C., Wingenfeld, K., Kuehl, L. K., Kaczmarczyk, M., Richter, S., Quante, A., Regen, F., Bajbouj, M., Zimmermann-Viehoff, F., Wiedemann, K., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.181 · Cited by 91
“Also, there was an attenuated cortisol inhibition in psychotic major depression after fludrocortisone also consistent with impaired MR function in these patients (Juruena et al, 2013; Lembke et al, 2013).”
BackgroundResultSchatzberg, A. F. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.916414 · Cited by 51
Self-citationRegulation of aldosterone secretion by mineralocorticoid receptor–mediated signaling
Chong, C., Hamid, A., Yao, T., Garza, A. E., Pojoga, L. H., Adler, G. K., Romero, J. R., & Williams, G. H. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0452 · Cited by 38
Self-citation
Metadata
- Authors
- Lembke, A., Gomez, R., Tenakoon, L., Keller, J., Cohen, G., Williams, G. H., Kraemer, F. B., & Schatzberg, A. F.
- Venue
- Psychoneuroendocrinology
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 38
- Issue
- 1
- Pages
- 115-121
- ISSN
- 0306-4530 (ISSN-L)
- OpenAlex
- W1974813832
- Cited by
- 53
- References
- 12
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.